Peptoids: Bio-inspired polymers as potential pharmaceuticals

Current Pharmaceutical Design

Volumn 17, Issue 25, 2011, Pages 2732-2747

  Dohm, Michelle T ^a   Kapoor, Rinki ^b   Barron, Annelise E ^a,b  

^a Stanford University   (United States)

^b STANFORD UNIVERSITY   (United States)

Author keywords

Amphipathic; Antimicrobial peptides; Host defense peptides; Lung surfactant; Mimic; Peptide; Peptidomimetic; Peptoids

Indexed keywords

ANTIINFECTIVE AGENT; ANTINEOPLASTIC AGENT; DIAGNOSTIC AGENT; GLYCINE DERIVATIVE; LUNG SURFACTANT; PEPTOID;

DRUG ACTIVITY; DRUG INDICATION; DRUG STRUCTURE; DRUG SYNTHESIS; HUMAN; NEOPLASM; NONHUMAN; POLYMERIZATION; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN FOLDING; PROTEIN STRUCTURE; REVIEW;

EID: 80053485066     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/138161211797416066     Document Type: Review

References (157)

1. Zuckermann RN, Kerr JM, Kent SBH, Moos WH. Efficient method for the preparation of peptoids oligo(N-substituted glycines) by submonomer solid-phase synthesis. J Am Chem Soc 1992; 114: 10646-47.
2. Simon RJ; Kania RS; Zuckermann RN; et al. Peptoids: a modular approach to drug discovery. Proc Natl Acad Sci USA 1992; 89: 9367-9371.
3. Sanborn TJ, Wu CW, Zuckermann RN, Barron AE. Extreme stability of helices formed by water-soluble poly-N-substituted glycines (polypeptoids) with alpha-chiral side chains. Biopolymers 2002; 63: 12-20.
4. Miller SM, Simon RJ, Ng S, Zuckermann RN, Kerr JM, Moos WH. Comparison of the proteolytic susceptibilities of homologous Lamino-acid, D-amino-acid, and N-substituted glycine peptide and peptoid oligomers. Drug Dev Res 1995; 35: 20-32.
5. Astle JM, Udugamasooriya DG, Smallshaw JE, Kodadek T. A VEGFR2 antagonist and other peptoids evade immune recognition. International Journal of Peptide Research 2008; 14: 223-227.
6. Gibbons JA, Hancock AA, Vitt CR, et al. Pharmacologic characterization of CHIR 2779, an N-substituted glycine peptoid with high-affinity binding for alpha 1-adrenoceptors. Pharmacology 1996; 277: 885-899.
7. Zuckermann RN, Kodadek T. Peptoids as potential therapeutics. Curr Opin Mol Ther 2009; 11: 299-307.
8. Fowler SA, Blackwell HE. Structure-function relationships in peptoids: recent advances toward deciphering the structural requirements for biological function. Org Biomol Chem 2009; 7: 1508-24.
9. Haynes RD, Meagher RJ, Won JI, Bogdan FM, Barron AE. Comblike, monodisperse polypeptoid drag-tags for DNA separations by end-labeled free-solution electrophoresis (ELFSE). Bioconj Chem 2005; 16: 929-938.
10. Meagher RJ, McCormick LC, Haynes RD, et al. Free-solution electrophoresis of DNA modified with drag-tags at both ends. Electrophoresis 2006; 27: 1702-1712.
11. Statz AR, Park JP, Chongsiriwatana NP, Barron AE, Messersmith PB. Surface-immobilised antimicrobial peptoids. Biofouling 2008; 24: 439-48.
12. Haynes RD. In Chemistry; Northwestern University: Evanston, 2008; Vol. Doctor of Philosophy.
13. Yoo B, Kirshenbaum K. Peptoid architectures: elaboration, actuation, and application. Curr Opin Chem Biol 2008; 12: 714-721.
14. Olsen CA. Peptoid-Peptide hybrid backbone architectures. ChemBioChem 2010; 11: 152-160.
15. Culf AS, Ouellette RJ. Solid-Phase synthesis of N-substituted glycine oligomers (α-peptoids) and derivatives. Molecules 2010; 15: 5282-5335.
16. Wu CW, Kirshenbaum K, Sanborn TJ, et al. Structural and spectroscopic studies of peptoid oligomers with alpha-chiral aliphatic side chains. J Am Chem Soc 2003; 125: 13525-13530.
17. Wu CW, Sanborn TJ, Huang K, Zuckermann RN, Barron AE. Peptoid oligomers with alpha-chiral, aromatic side chains: sequence requirements for the formation of stable peptoid helices. J Am Chem Soc 2001; 123: 6778-6784.
18. Wu CW, Sanborn TJ, Zuckermann RN, Barron AE. Peptoid oligomers with alpha-chiral, aromatic side chains: effects of chain length on secondary structure. J Am Chem Soc 2001; 123: 2958-2963.
19. Armand P, Kirshenbaum K, Goldsmith RA, et al. NMR determination of the major solution conformation of a peptoid pentamer with chiral side chains. Proc Natl Acad Sci USA 1998; 95: 4309-4314.
20. Brown NJ, Johansson J, Barron AE. Biomimicry of surfactant protein C. Acc Chem Res 2008; 41: 1409-1417.
21. Czyzewski AM, Barron AE. Protein and peptide biomimicry: gold mining inspiration from nature's ingenuity. AlChE J 2008; 54: 1-7.
22. Wu CW, Barron AE. In Biomimetic Materials and Design, A.K. Dillow, ed.; Marcel-Dekker: New York, 2002: pp. 565-633.
23. Gellman SH. Foldamers: a manifesto. Acc Chem Res 1998; 31: 173-180.
24. Creuwels L, vanGolde LMG, Haagsman HP. The pulmonary surfactant system: biochemical and clinical aspects. Lung 1997; 175: 1-39.
25. Goerke J, Clements JA. In The Handbook of Physiology, Sec 3, The Respiratory System; The American Physiological Society: Bethesda, MD, 1986; Vol. 3: pp. 247-262.
26. Notter RH. Lung surfactants: basic science and clinical applications, Marcel Dekker: New York 2000.
27. Serrano AG, Perez-Gil J. Protein-lipid interactions and surface activity in the pulmonary surfactant system. Chem Phys Lipids 2006; 141: 105-118.
28. Zuo YY, Veldhuizen RAW, Neumann AW, Petersen NO, Possmayer F. Current perspectives in pulmonary surfactant - inhibition, enhancement and evaluation. Biochim Biophys Acta 2008; 1778: 1947-1977.
29. Orgeig S, Bernhard W, Biswas SC, et al. The anatomy, physics, and physiology of gas exchange surfaces: is there a universal function for pulmonary surfactant in animal respiratory structures? Integr Comp Biol 2007; 47: 610-627.
30. Perez-Gil J, Weaver TE. Pulmonary surfactant pathophysiology: current models and open questions. Physiology 2010; 25: 132-141.
31. Veldhuizen EJA, Haagsman HP. Role of pulmonary surfactant components in surface film formation and dynamics. Biochim Biophys Acta 2000; 1467: 255-270.
32. Hawgood S, Schiffer K. Structures and properties of the surfactantassociated proteins. Annu Rev Physiol 1991; 53: 375-394.
33. Johansson J, Curstedt T, Robertson B. The proteins of the surfactant system. Eur Respir J 1994; 7: 372-391.
34. Perez-Gil J. Structure of pulmonary surfactant membranes and films: the role of proteins and lipid-protein interactions. Biochim Biophys Acta 2008; 1778: 1676-1695.
35. Avery ME, Mead J. Surface properties in relation to atelectasis and hyaline membrane disease. Am J Dis Child 1959; 97: 517-523.
36. Moya FR, Maturana A. Animal-derived surfactants versus past and current synthetic surfactants: current status. Clin Perinatol 2007; 34: 145-177.
37. Mingarro I, Lukovic D, Vilar M, Perez-Gil J. Synthetic pulmonary surfactant preparations: new developments and future trends. Curr Med Chem 2008; 15: 393-403.
38. Pison U, Seeger W, Buchhorn R, et al. Surfactant abnormalities in patients with respiratory-failure after multiple trauma. Am Rev Respir Dis 1989; 140: 1033-1039.
39. Lewis JE, Jobe AH. Surfactant and the adult respiratory distress syndrome. Am Rev Respir Dis 1993; 147: 218-233.
40. Bosma KJ, Taneja R, Lewis JF. Pharmacotherapy for prevention and treatment of acute respiratory distress syndrome. Drugs 2010; 70: 1255-1282.
41. Playfor SD, Nootigattu VKT. Exogenous surfactant in paediatric acute lung injury and acute respiratory distress syndrome. Curr Drug Saf 2006; 10: 159-168.
42. Lewis JF, Veldhuizen R. The role of exogenous surfactant in the treatment of acute lung injury. Annu Rev Physiol 2003; 65: 613-642.
43. Robertson B, Johansson J, Curstedt T. Synthetic surfactants to treat neonatal lung disease. Mol Med Today 2000; 6: 119-124.
44. Blanco O, Perez-Gil J. Biochemical and pharmacological differences between preparations of exogenous natural surfactant used to treat respiratory distress syndrome: role of the different components in an efficient pulmonary surfactant. Eur J Pharmacol 2007; 568: 1-15.
45. Almlen A, Stichtenoth G, Linderholm B, et al. Surfactant proteins B and C are both necessary for alveolar stability at end expiration in premature rabbits with respiratory distress syndrome. J Appl Physiol 2008; 104: 1101-1108.
46. Johansson J, Szyperski T, Curstedt T, Wuthrich K. The NMR structure of the pulmonary surfactant-associated polypeptide SP-C in an apolar solvent contains a valyl-rich α-helix. Biochemistry 1994; 33.
47. Haagsman HP, Diemel RV. Surfactant-associated proteins: functions and structural variation. Comp Biochem Physiol A Mol Integr Physiol 2001; 129: 91-108.
48. Creuwels LA, Boer EH, Demel RA, van Golde LMG, Haagsman HP. Neutralization of the positive charges of surfactant protein C: effects on structure and function. J Biol Chem 1995; 270: 16225-16229.
49. Kramer A, Wintergalen A, Sieber M, Galla HJ, Amrein M, Guckenberger R. Distribution of the surfactant-associated protein C within a lung surfactant model film investigated by near-field optical microscopy. Biophys J 2000; 78: 458-465.
50. Bi XH, Flach CR, Perez-Gil J, et al. Secondary structure and lipid interactions of the N-terminal segment of pulmonary surfactant SPC in Langmuir films: IR reflection-absorption spectroscopy and surface pressure studies. Biochemistry 2002; 41: 8385-8395.
51. Alonso C, Waring A, Zasadzinski JA. Keeping lung surfactant where it belongs: protein regulation of two-dimensional viscosity. Biophys J 2005; 89: 266-273.
52. Nakorn PN, Meyer MC, Flach CR, Mendelsohn R, Galla HJ. Surfactant protein C and lung function: new insights into the role of alpha-helical length and palmitoylation. Eur Biophys J 2007; 36: 477-489.
53. Plasencia I, Baumgart F, Andreu D, Marsh D, Perez-Gil J. Effect of acylation on the interaction of the N-terminal segment of pulmonary surfactant protein SP-C with phospholipid membranes. Biochim Biophys Acta 2008; 1778: 1274-1282.
54. Takei T, Hashimoto Y, Aiba T, Sakai K, Fujiwara T. The surface properties of chemically synthesized peptides analogous to human pulmonary surfactant protein C. Biol Pharm Bull 1996; 19: 1247-1253.
55. Ikegami M, Jobe AH. Surfactant protein-C in ventilated premature lamb lung. Pediatr Res 1998; 44: 860-864.
56. Nilsson G, Gustafsson M, Vandenbussche G, et al. Synthetic peptide-containing surfactants - evaluation of transmembrane versus amphipathic helices and surfactant protein C poly-valyl to poly-leucyl substitution. Eur J Biochem 1998; 255: 116-124.
57. Hawgood S, Ogawa A, Yukitake K, et al. Lung function in premature rabbits treated with recombinant human surfactant protein C. Am J Respir Crit Care Med 1996; 154: 484-490.
58. Lukovic D, Plasencia I, Taberner FJ, et al. Production and characterisation of recombinant forms of human pulmonary surfactant protein C (SP-C): structure and surface activity. Biochim Biophys Acta 2006; 1758: 509-518.
59. Taut FJH, Rippin G, Schenk P, et al. A search for subgroups of patients with ARDS who may benefit from surfactant replacement therapy: a pooled analysis of five studies with recombinant surfactant protein-C surfactant (Venticute). Chest 2008; 134: 724-732.
60. Andersson M, Curstedt T, Jornvall H, Johansson J. An amphipathic helical motif common to tumourolytic polypeptide NK-Lysin and pulmonary surfactant polypeptide SP-B. FEBS Lett 1995; 362: 328-332.
61. Hawgood S, Derrick M, Poulain F. Structure and properties of surfactant protein B. Biochim Biophys Acta 1998; 1408: 150-160.
62. Zaltash S, Palmblad M, Curstedt T, Johansson J, Persson B. Pulmonary surfactant protein B: a structural model and a functional analogue. Biochim Biophys Acta 2000; 1466: 179-186.
63. Vandenbussche G, Clercx A, Clercx M, et al. Secondary structure and orientation of the surfactant protein SP-B in a lipid environment - a Fourier-transform infrared-spectroscopy study. Biochemistry 1992; 31: 9169-9176.
64. Waring A, Taeusch HW, Bruni R, Amirkhanian JD, Fan BR, Stevens R, Young J. Synthetic amphipathic sequences of surfactant protein-B mimic several physicochemical and in vivo properties of native pulmonary surfactant proteins. Pept Res 1989; 2: 308-313.
65. Bruni R, Taeusch HW, Waring AJ. Surfactant protein-B - lipid interactions of synthetic peptides representing the amino-terminal amphipathic domain. Proc Natl Acad Sci USA 1991; 88: 7451-7455.
66. Baatz JE, Sarin V, Absolom DR, Baxter C, Whitsett JA. Effects of surfactant-associated protein SP-B synthetic analogs on the structure and surface-activity of model membrane bilayers. Chem Phys Lipids 1991; 60: 163-178.
67. Gordon LM, Horvath S, Longo ML, et al. Conformation and molecular topography of the N-terminal segment of surfactant protein B in structure-promoting environments. Protein Sci 1996; 5: 1662-1675.
68. Gordon LM, Lee KYC, Lipp MM, Zasadzinski JA, Walther FJ, Sherman MA, Waring AJ. Conformational mapping of the Nterminal segment of surfactant protein B in lipid using C-13-enhanced Fourier transform infrared spectroscopy. J Pept Res 2000; 55: 330-347.
69. Cochrane CG, Revak SD. Pulmonary surfactant protein-B (SP-B) - structure-function-relationships. Science 1991; 254: 566-568.
70. Seurynck SL, Patch JA, Barron AE. Simple, helical peptoid analogs of lung surfactant protein B. Chem Biol 2005; 12: 77-88.
71. Veldhuizen EJA, Waring AJ, Walther FJ, Batenburg JJ, van Golde LMG, Haagsman HP. Dimeric N-terminal segment of human surfactant protein B (dSP-B1-25) has enhanced surface properties compared to monomeric SP-B1-25. Biophys J 2000; 79: 377-384.
72. Waring AJ, Walther F, Gordon LM, et al. The role of charged amphipathic helices in the structure and function of surfactant protein B. J Pept Res 2005; 66: 364-374.
73. Cochrane CG. Surfactant protein B and mimic peptides in the function of pulmonary surfactant. FEBS Lett 1998; 430: 424-424.
74. Cochrane CG, Revak SD, Merritt A, et al. The efficacy and safety of KL(4)-surfactant in infants with respiratory distress syndrome. Am J Respir Crit Care Med 1996; 153: 404-410.
75. Moya FR, Gadzinowski J, Bancalari E, et al. A multicenter, randomized, masked, comparison trial of lucinactant, colfosceril palmitate, and beractant for the prevention of respiratory distress syndrome among very preterm infants. Pediatrics 2005; 115: 1018-1029.
76. Sinha SK, Lacaze-Masmonteil T, Soler AVI, et al. A multicenter, randomized, controlled trial of lucinactant versus poractant alfa among very premature infants at high risk for respiratory distress syndrome. Pediatrics 2005; 115: 1030-1038.
77. Wiswell TE, Knight GR, Finer NN, et al. A multicenter, randomized, controlled trial comparing surfaxin (lucinactant) lavage with standard care for treatment of meconium aspiration syndrome. Pediatrics 2002; 109: 1081-1087.
78. Tanaka Y, Takei T, Aiba T, Masuda K, Kiuchi A, Fujiwara T. Development of synthetic lung surfactants. J Lipid Res 1986; 27: 475-485.
79. Wu CW, Seurynck SL, Lee KYC, Barron AE. Helical peptoid mimics of lung surfactant protein C. Chem Biol 2003; 10: 1057-1063.
80. Brown NJ, Wu CW, Seurynck-Servoss SL, Barron AE. Effects of hydrophobic helix length and side chain chemistry on biomimicry in peptoid analogues of SP-C. Biochemistry 2008; 47: 1808-1818.
81. Brown NJ, Dohm MT, Bernardino de la Serna J, Barron AE. Nterminal alkylation improves biomimicry of a peptoid-based analogue of SP-C. Biophys J; accepted.
82. Seurynck SL, Brown NJ, Wu CW, et al. Optical monitoring of bubble size and shape in a pulsating bubble surfactometer. J Appl Physiol 2005; 99: 624-633.
83. Seurynck-Servoss SL, Dohm MT, Barron AE. Effects of including an N-terminal insertion region and arginine-mimetic side chains in helical peptoid analogues of lung surfactant protein B. Biochemistry 2006; 45: 11809-11818.
84. Dohm MT, Seurynck-Servoss SL, Seo J, Zuckermann RN, Barron AE. Close mimicry of lung surfactant protein B by clicked dimers of helical, cationic peptoids. Biopolymers (Peptide Sci) 2009; 92: 538-553.
85. Dohm MT, Brown NJ, Seurynck-Servoss SL, Bernardino de la Serna J, Barron AE. Mimicking SP-C palmitoylation on a peptoidbased SP-B analogue markedly improves surface activity. Biochim Biophys Acta- Biomem 2010; 1798: 1663-1678.
86. Dohm MT, Mowery BP, Czyzewski AM, Stahl SS, Gellman SH, Barron AE. Biophysical mimicry of lung surfactant protein B by random nylon-3 copolymers. J Am Chem Soc 2010; 132: 7957-7967.
87. Dohm MT, Barron AE. Surface activity determinants in peptoidbased biophysical mimicry of lung surfactant protein B. PLoS One; In Revision.
88. Czyzewski AM, McCaig LM, Dohm MT, et al. The in vivo efficacy of biomimetic, peptoid-enhanced surfactants in treating acute lung injury. submitted.
89. Kunin CM. Resistance to antimicrobial drugs--a worldwide calamity. Ann Intern Med 1993; 118: 557-61.
90. Boucher HW, Talbot GH, Bradley JS, et al. Bad bugs, no drugs: no ESKAPE! An update from the Infectious Diseases Society of America. Clin Infect Dis 2009; 48: 1-12.
91. Glickman MS, Cahill SM, Jacobs WR. The mycobacterium tuberculosis cmaA2 gene encodes a mycolic acid transcyclopropane synthetase. J Biol Chem 2001; 276: 2228-2233.
92. Hancock REW, Sahl HG. Antimicrobial and host-defense peptides as new anti-infective therapeutic strategies. Nat Biotechnol 2006; 24: 1551-1557.
93. Zasloff M. Antimicrobial peptides of multicellular organisms. Nature 2002; 415: 389-395.
94. Matsuzaki K. Why and how are peptide-lipid interactions utilized for self-defense? Magainins and tachyplesins as archetypes. Biochim Biophys Acta 1999; 1462: 1-10.
95. Matsuzaki K, Murase O, Fujii N, Miyajima K. Translocation of a channel-forming antimicrobial peptide, magainin 2, across lipid bilayers by forming a pore. Biochemistry 1995; 34: 6521-6.
96. Matsuzaki K, Sugishita K, Fujii N, Miyajima K. Molecular-Basis for membrane selectivity of an antimicrobial peptide, magainin-2. Biochemistry 1995; 34: 3423-3429.
97. Subbalakshmi C, Sitaram N. Mechanism of antimicrobial action of indolicidin. FEMS Microbiol Lett 1998; 160: 91-6.
98. Park CB, Kim HS, Kim SC. Mechanism of action of the antimicrobial peptide buforin II: Buforin II kills microorganisms by penetrating the cell membrane and inhibiting cellular functions. Biochem Biophys Res Commun 1998; 244: 253-257.
99. Hale JD, Hancock REW. Alternative mechanisms of action of cationic antimicrobial peptides on bacteria. Expert Rev Anti Infect Ther 2007; 5: 951-959.
100. Otvos Jr. L. Antibacterial peptides and proteins with multiple cellular targets. J Pept Sci 2005; 11: 697-706.
101. Frantz MC, Wipf P. Mitochondria as a target in treatment. Environ Mol Mutag 2010; 51: 462-475.
102. Hilpert K, McLeod B, Yu J, et al. Short cationic antimicrobial peptides interact with ATP. Antimicrob Agents Chemother 2010; 54: 4480-4483.
103. Bessalle R, Kapitkovsky A, Gorea A, Shalit I, Fridkin M. All-Dmagainin: chirality, antimicrobial activity and proteolytic resistance. FEBS Lett 1990; 274: 151-5.
104. Brogden KA. Antimicrobial peptides: pore formers of metabolic inhibitors in bacteria? Nat Rev Microbiol 2005; 3: 238-250.
105. Arnt L, Tew GN. New poly(phenyleneethynylene)s with cationic, facially amphipathic structures. J Am Chem Soc 2002; 124: 7664-7665.
106. Porter EA, Wang X, Lee HS, Weisblum B, Gellman SH. Nonhaemolytic beta-amino-acid oligomers. Nature 2000; 404: 565.
107. Porter EA, Weisblum B, Gellman SH. Mimicry of host-defense peptides by unnatural oligomers: antimicrobial beta-peptides. J Am Chem Soc 2002; 124: 7324-30.
108. Tew GN, Liu D, Chen B, et al. De novo design of biomimetic antimicrobial polymers. Proc Natl Acad Sci USA 2002; 99: 5110-4.
109. Duclohier H. Antimicrobial peptides and peptaibols, substitutes for conventional antibiotics. Curr Pharm Des 2010; 16: 3212-3213.
110. Ilker MF, Nusslein K, Tew GN, Coughlin EB. Tuning the hemolytic and antibacterial activities of amphiphilic polynorbornene derivatives. J Am Chem Soc 2004; 126: 15870-15875.
111. Tang H, Doerksen RJ, Tew GN. Synthesis of urea oligomers and their antibacterial activity. Chemical Communications (Cambridge, England) 2005; 28: 1537-1539.
112. Barron AE, Zuckermann RN. Bioinspired polymeric materials: inbetween proteins and plastics. Curr Opin Struct Biol 1999; 3: 681-687.
113. Kirshenbaum K, Zuckermann RN, Dill KA. Designing polymers that mimic biomolecules. Curr Opin Struct Biol 1999; 9: 530-535.
114. Chongsiriwatana NP, Patch JA, Czyzewski AM, et al. Peptoids that mimic the structure, function, and mechanism of helical antimicrobial peptides. Proc Natl Acad Sci USA 2008; 105: 2794-2799.
115. Patch JA, Barron AE. Helical peptoid mimics of magainin-2 amide. J Am Chem Soc 2003; 125: 12092-12093.
116. Patch JA, Barron AE. Mimicry of bioactive peptides via nonnatural, sequence-specific peptidomimetic oligomers. Curr Opin Chem Biol 2002; 6: 872-877.
117. Czyzewski AM, Kapoor R, Chongsiriwatana NP, et al. Ampetoids as selective, broad-spectrum mimics of antimicrobial peptides. Antimicrob Agents Chemother; submitted.
118. Czyzewski AM, Jenseen H, Dohm MT, et al. B. In vitro and in vivo antimicrobial activity of peptoids against multi-drug-resistant bacteria submitted.
119. Makovitzki A, Avrahami D, Shai Y. Ultrashort antibacterial and antifungal lipopeptides. Proceedings of the National Academy of Sciences USA 2006; 103: 15997-16002.
120. Chongsiriwatana NP, Miller TM, Wetzler M, et al. Short alkylated peptoid mimics of antimicrobial lipopeptides. Antimicrob Agents Chemother 2011; 55: 417-20.
121. Kapoor R, Eimerman PE, Hardy HW, Cirillo J, Contag CH, Barron AE. Efficacy of antimicrobial peptoids against mycobacterium. Antimicrob Agents Chemother 2011; 55(6): 3054-7.
122. Shai Y. Mode of action of membrane active antimicrobial peptides. Biopolymers 2002; 66: 236-48.
123. Maulucci N, Izzo I, Bifulco G, et al. Synthesis, structures, and properties of nine-, twelve-, and eighteen-membered Nbenzyloxyethyl cyclic alpha-peptoids. Chem Commun (Camb) 2008: 3927-9.
124. Unciti-Broceta A, Diezmann F, Ou-Yang CY, Fara MA, Bradley M. Synthesis, penetrability and intracellular targeting of fluorescein-tagged peptoids and peptide-peptoid hybrids. Bioorg Med Chem 2009; 17: 959-66.
125. Zhu WL, Park Y, Park IS, Park YS, Kim Y, Hahm KS, Shin SY. Improvement of bacterial cell selectivity of melittin by a single Trp mutation with a peptoid residue. Protein Pept Lett 2006; 13: 719-25.
126. Zhu WL, Hahm KS, Shin SY. Cathelicidin-derived Trp/Pro-rich antimicrobial peptides with lysine peptoid residue (Nlys): therapeutic index and plausible mode of action. J Pept Sci 2007; 13: 529-35.
127. Gobbo M, Benincasa M, Bertoloni G, et al. Substitution of the arginine/leucine residues in apidaecin Ib with peptoid residues: effect on antimicrobial activity, cellular uptake, and proteolytic degradation. J Med Chem 2009; 52: 5197-206.
128. Park M, Jardetzky TS, Barron AE. NMEGylation as a potential method for enhancing the bioavailability of peptide-based therapeutics. Biopolymers (Peptide Sci) 2010; in revision.
129. Park M, Matsuura H, Lamb RA, Barron AE, Jardetzky TS. A fluorescence polarization assay using an engineered human respiratory syncytial virus F protein as a direct screening platform. Anal Biochem In press.
130. Goodson B, Ehrhardt A, Ng S, et al. Characterization of novel antimicrobial peptoids. Antimicrob Agents Chemother 1999; 43: 1429-34.
131. Cuellar LE, Fernandez-Maldonado E, Rosenthal VD, et al. Deviceassociated infection rates and mortality in intensive care units of Peruvian hospitals: findings of the International Nosocomial Infection Control Consortium. Rev Panam Salud Publica 2008; 24: 16-24.
132. Kola A, Schwab F, Barwolff S, et al. Is there an association between nosocomial infection rates and bacterial cross transmissions? Crit Care Med 2010; 38: 46-50.
133. Kovaleva J, Meessen NE, Peters FT, et al. Is bacteriologic surveillance in endoscope reprocessing stringent enough? Endoscopy 2009; 41: 913-6.
134. Mah TF, O'Toole GA. Mechanisms of biofilm resistance to antimicrobial agents. Trends Microbiol 2001; 9: 34-9.
135. Lewis K. Riddle of biofilm resistance. Antimicrob Agents Chemother 2001; 45: 999-1007.
136. Aaron SD, Ferris W, Henry DA, Speert DP, MacDonald NE. Multiple combination bactericidal antibiotic testing for patients with cystic fibrosis infected with Burkholderia cepacia. Am J Respir Crit Care Med 2000; 161: 1206-1212.
137. Anderson GG, Moreau-Marquis S, Stanton BA, O'Toole GA. In vitro analysis of tobramycin-treated Pseudomonas aeruginosa biofilms on cystic fibrosis-derived airway epithelial cells. Infect Immun 2008; 76: 1423-33.
138. Killgore KM, March KL, Guglielmo BJ. Risk factors for community-acquired ciprofloxacin-resistant Escherichia coli urinary tract infection. Ann Pharmacother 2004; 38: 1148-52.
139. Justice SS, Hung C, Theriot JA, et al. Differentiation and developmental pathways of uropathogenic Escherichia coli in urinary tract pathogenesis. Proc Natl Acad Sci USA 2004; 101: 1333-8.
140. Kapoor R, Mayken WW, Czyzewski AM, Spormann AM, Barron AE. Antimicrobial peptoids are effective against pseudomonas aeruginosa biofilms. Antimicrob Agents Chemother 2011; 55(6): 3058-62.
141. Numata M, Chu H, W., Dakhama A, Voelker DR. Pulmonary surfactant phosphatidylglycerol inhibits respiratory syncytial virusinduced inflammation and infection. Proc Natl Acad Sci USA 2009; 107: 302-325.
142. Lipinski CA. Drug-like properties and the causes of poor solubility and poor permeability. J Pharmacol Toxicol Methods 2000; 44: 235-49.
143. Nguyen JT, Porter M, Amoui M, Miller WT, Zuckermann RN, Lim WA. Improving SH3 domain ligand selectivity using a non-natural scaffold. Chem Biol 2000; 7: 463-73.
144. Nguyen JT, Turck CW, Cohen FE, Zuckermann RN, Lim WA. Exploiting the basis of proline recognition by SH3 and WW domains: design of N-substituted inhibitors. Science 1998; 282: 2088-92.
145. Zuckermann RN, Martin EJ, Spellmeyer DC, et al. Discovery of nanomolar ligands for 7-transmembrane G-protein-coupled receptors from a diverse N-(substituted)glycine peptoid library. J Med Chem 1994; 37: 2678-85.
146. Murphy JE, Uno T, Hamer JD, Cohen FE, Dwarki V, Zuckermann RN. A combinatorial approach to the discovery of efficient cationic peptoid reagents for gene delivery. Proc Natl Acad Sci USA 1998; 95: 1517-22.
147. Gocke AR, Udugamasooriya DG, Archer CT, Lee J, Kodadek T. Isolation of antagonists of antigen-specific autoimmune T cell proliferation. Chem Biol 2009; 16: 1133-9.
148. Lim HS, Archer CT, Kodadek T. Identification of a peptoid inhibitor of the proteasome 19S regulatory particle. J Am Chem Soc 2007; 129: 7750-1.
149. Udugamasooriya DG, Dineen SP, Brekken RA, Kodadek T. A peptoid antibody surrogate that antagonizes VEGF receptor 2 activity. J Am Chem Soc 2008; 130: 5744-52.
150. Udugamasooriya DG, Dunham G, Ritchie C, Brekken RA, Kodadek T. The pharmacophore of a peptoid VEGF receptor 2 antagonist includes both side chain and main chain residues. Bioorg Med Chem Lett 2008; 18: 5892-4.
151. Udugamasooriya DG, Ritchie C, Brekken RA, Kodadek T. A peptoid antagonist of VEGF receptor 2 recognizes a 'hotspot' in the extracellular domain distinct from the hormone-binding site. Bioorg Med Chem 2008; 16: 6338-43.
152. Lynn KD, Udugamasooriya DG, Roland CL, Castrillon DH, Kodadek TJ, Brekken RA. GU81, a VEGFR2 antagonist peptoid, enhances the anti-tumor activity of doxorubicin in the murine MMTV-PyMT transgenic model of breast cancer. BMC Cancer 2003; 10: 397.
153. Mowery BP, Lee SE, Kissounko DA, et al. Mimicry of antimicrobial host-defense peptides by random copolymers. J Am Chem Soc 2007; 129: 15474-6.
154. Epand RF, Mowery BP, Lee SE, Stahl SS, Lehrer RI, Gellman SH. Dual mechanism of bacterial lethality for a cationic sequencerandom copolymer that mimics host-defense antimicrobial peptides. J Mol Biol 2008; 379: 38-50.
155. Mowery BP, Lindner AH, Weisblum B, Stahl SS, Gellman SH. Structure-activity relationships among random nylon-3 copolymers that mimic antibacterial host-defense peptides. J Am Chem Soc 2009; 131: 9735-45.
156. Ryan MA, Akinbi HT, Serrano AG, et al. Antimicrobial activity of native and synthetic surfactant protein B peptides. J Immunol 2006; 176: 416-25.
157. Wang Y, Lin H, Tullman R, Jewell CF, Jr., Weetall ML, Tse FL. Absorption and disposition of a tripeptoid and a tetrapeptide in the rat. Biopharm Drug Dispos 1999; 20: 69-75.